CA2936366C - Anticorps dirigés contre l’interleukine-33 (il-33) - Google Patents

Anticorps dirigés contre l’interleukine-33 (il-33)

Info

Publication number
CA2936366C
CA2936366C CA2936366A CA2936366A CA2936366C CA 2936366 C CA2936366 C CA 2936366C CA 2936366 A CA2936366 A CA 2936366A CA 2936366 A CA2936366 A CA 2936366A CA 2936366 C CA2936366 C CA 2936366C
Authority
CA
Canada
Prior art keywords
seq
nos
isolated
binding agent
chain polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2936366A
Other languages
English (en)
Other versions
CA2936366A1 (fr
Inventor
Robert A. Horlick
David J. King
Andrew John MCKNIGHT
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Priority claimed from PCT/US2015/010785 external-priority patent/WO2015106080A2/fr
Publication of CA2936366A1 publication Critical patent/CA2936366A1/fr
Application granted granted Critical
Publication of CA2936366C publication Critical patent/CA2936366C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne un polypeptide à chaîne lourde d’immunoglobuline isolé et un polypeptide à chaîne légère d’immunoglobuline isolé qui se lient à l’interleukine-33 (IL-33). L’invention concerne en outre un agent de liaison à l’IL-33 qui comprend le polypeptide à chaîne lourde d’immunoglobuline et le polypeptide à chaîne légère d’immunoglobuline mentionnés ci-dessus. L’invention a également trait à des vecteurs, des compositions et des procédés associés d’utilisation de l’agent de liaison à l’IL-33 pour traiter un trouble chez un mammifère qui réagit à l’inhibition d’IL-33.
CA2936366A 2014-01-10 2015-01-09 Anticorps dirigés contre l’interleukine-33 (il-33) Active CA2936366C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925946P 2014-01-10 2014-01-10
US61/925,946 2014-01-10
PCT/US2015/010785 WO2015106080A2 (fr) 2014-01-10 2015-01-09 Anticorps dirigés contre l'interleukine-33 (il-33)

Publications (2)

Publication Number Publication Date
CA2936366A1 CA2936366A1 (fr) 2015-07-16
CA2936366C true CA2936366C (fr) 2025-07-08

Family

ID=

Similar Documents

Publication Publication Date Title
US11999783B2 (en) Method of treating autoimmune disease with antibodies against IL-33
JP7721585B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
CA2936366C (fr) Anticorps dirigés contre l’interleukine-33 (il-33)
RU2829846C2 (ru) Антитела, направленные против интерлейкина-33 (il-33)
HK1231082B (en) Antibodies directed against interleukin-33 (il-33)
HK1231082A1 (en) Antibodies directed against interleukin-33 (il-33)
HK40086847A (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1252009B (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1250941B (en) Antibodies directed against interleukin 36 receptor (il-36r)